Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 1, 2003, Pages 166-171

  Song, D Y ^a   Jones, R J ^a   Welsh, J S ^a   Haulk, T L ^a   Korman, L T ^a   Noga, S ^a   Goodman, S ^a   Herman, M ^a   Mann, R ^b   Marcellus, D ^a   Vogelsang, G ^a   Ambinder, R F ^a   Abrams, Ross A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

Bone marrow transplantation; Lymphoma; Total body irradiation

Indexed keywords

BONE; DISEASE CONTROL; DOSIMETRY; IRRADIATION; RADIOTHERAPY;

BONE MARROW TRANSPLANTATION (BMT);

ONCOLOGY;

BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ELECTRIC CURRENT; ESOPHAGITIS; FEMALE; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; MALE; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RADIOSENSITIVITY; REFRACTORY PERIOD; SAFETY; SECOND CANCER; VOMITING; WHOLE BODY RADIATION;

EID: 0042566152     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00508-X     Document Type: Article

References (29)

1. Armitage J.O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood. 73:1989;1749-1753.
2. Appelbaum F.R., Sullivan K.M., Buckner C.D., et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol. 5:1987;1340-1347.
3. Mundt A.J., Williams S.F., Hallahan D. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma Patterns of failure and implications for involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 39:1997;617-625.
4. Jones R.J., Ambinder R.F., Piantadosi S., et al. Evidence of a graft-versus-tumor lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 77:1991;649-653.
5. Brasacchio R., Constine L., Rapoport A., et al. Dose escalation of consolidation radiation therapy (involved field) following autologous bone marrow transplant for recurrent Hodgkin's disease and lymphoma. Int J Radiat Oncol Biol Phys. 36:(Suppl. 1):1996;171.
6. Phillips G.L., Fay J.W., Herzig R.H., et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood. 75:1990;831-838.
7. Pezner R.D., Nademanee A., Niland J.C., et al. Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol. 34:1995;23-29.
8. Rapoport A.P., Rowe J.M., Kouides P.A., et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma Value of pretransplant disease status for predicting outcome . J Clin Oncol. 11:1993;2351-2361.
9. Poen J.C., Hoppe R.T., Horning S.J. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease The impact of involved field radiotherapy on patterns of failure and survival . Int J Radiat Oncol Biol Phys. 36:1996;3-12.
10. Abrams R.A., Liu P.C., Ambinder R.F., et al. Hodgkin and non-Hodgkin lymphoma Local-regional radiation therapy after bone marrow transplantation . Radiology. 203:1997;865-870.
11. Constine L.S., Rapoport A.P. Hodgkin's disease, bone marrow transplantation, and involved field radiation therapy Coming full circle from 1902 to 1996 . Int J Radiat Oncol Biol Phys. 36:1996;253-255.
12. Anderson J., Litzow M., Appelbaum F., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease The 21-year Seattle experience . J Clin Oncol. 11:1993;2342-2350.
13. O'Quigley J., Chevpet S. Methods for dose finding studies in cancer clinical trials A review and results of a Monte Carlo study . Stat Med. 10:1991;1647-1664.
14. Noga S.J., Vogelsang G.B., Seber A., et al. The incidence of GVHD, but not engraftment is affected by cyclosporine-A (CSA) duration following transplantation with CD34+ augmented/elutriated (A/E) marrow. Abstract Blood. 86:(Suppl. 1):1995;395A.
15. Jones R.J., Piantadosi S., Mann R.B., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 8:1990;527-537.
16. Jones R.J., Vogelsang G.B., Hess A.D., et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet. 1:1989;753-758.
17. Radiation Therapy Oncology Group. (1/17/00). RTOG Acute Radiation Morbidity Scoring Criteria, RTOG/EORTC Late Radiation Morbidity Scoring Schema. [on-line]. Available: www.rtog.org/members/toxicity.
18. Apostolidis J., Foran J.M., Johnson P.W.M., et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol. 17:1999;216-221.
19. Philip T., Armitage J.O., Spitzer G. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 316:1987;1493-1498.
20. Takvorian T., Canellos G.P., Ritz J., et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 316:1987;1499-1505.
21. Mundt A.J., Sibley G., Williams S., et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed-refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys. 33:1995;261-270.
22. Price A., Cunningham D., Horwich A., et al. Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease. Eur J Cancer. 30A:1994;903-907.
23. Hall E.J., Brenner D.J. The dose-rate effect revisited Radiobiological considerations of importance in radiotherapy . Int J Radiat Oncol Biol Phys. 21:1991;1403-1414.
24. Cardozo B.L., Zoetelief H., van Bekkum D.K., et al. Lung damage following bone marrow transplantation I. The contribution of radiation . Int J Radiat Oncol Biol Phys. 11:1985;907-914.
25. Ozsahin M., Belkacemi Y., Pene F., et al. Total-body irradiation and cataract incidence A randomized comparison of two instantaneous dose rates . Int J Radiat Oncol Biol Phys. 28:1993;343-347.
26. Peters L.J., Withers H.R., Cundiff J.H., et al. Radiobiological considerations in the use of total body irradiation for bone-marrow transplantation. Radiology. 131:1979;243-247.
27. Jules-Elysee K., Stover D.E., Yahalom J., et al. Pulmonary complications in lymphoma patients treated with high-dose therapy and autologous bone marrow transplantation. Am Rev Respir Dis. 6:1992;485-491.
28. Petersen F.B., Appelbaum F.R., Hill R., et al. Autologous marrow transplantation for malignant lymphoma A report of 101 cases from Seattle . J Clin Oncol. 8:1990;638-647.
29. Reece D.E., Barnett M.J., Connors J.M., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 9:1991;1871-1879.